OPEN ACCESS

ORIGINAL ARTICLE

MED12 is recurrently mutated in Middle Eastern colorectal cancer

Abdul K Siraj,¹ Tariq Masoodi,¹ Rong Bu,¹ Poyil Pratheeshkumar,¹ Nasser Al-Sanea,² Luai H Ashari,² Alaa Abduljabbar,² Samar Alhomoud,² Fouad Al-Dayel,³ Fowzan S Alkuraya,^{4,5} Khawla S Al-Kuraya¹

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2016-313334>).

¹Human Cancer Genomic Research, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

²Department of Surgery and Colorectal Section, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

³Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

⁴Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

⁵Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

Correspondence to

Dr Khawla S Al-Kuraya, Human Cancer Genomic Research, King Faisal Specialist Hospital and Research Centre, Research Centre at KFNCRC, MBC#98-16, P.O. Box 3354, Riyadh 11211, Saudi Arabia; kkuraya@kfshrc.edu.sa

Received 31 October 2016

Revised 05 January 2017

Accepted 12 January 2017

Published Online First

31 January 2017

ABSTRACT

Objective Colorectal cancer (CRC) is a common cancer and a leading cause of cancer deaths. Previous studies have identified a number of key steps in the evolution of CRC but our knowledge of driver mutations in CRC remains incomplete. Recognising the potential of studying different human populations to reveal novel insights in disease pathogenesis, we conducted genomic analysis of CRC in Saudi patients.

Design In the discovery phase of the study, we conducted whole genome sequencing of tumour and corresponding germline DNA in 27 patients with CRC. In addition to known driver mutations, we identified three *MED12* somatic mutations. In the replication phase, we employed a next-generation sequencing approach to capture and sequence *MED12* and other candidate genes in a larger sample of 400 patients with CRC and confirmed the enrichment for recurrent *MED12* mutations.

Results In order to gain insight into a plausible biological mechanism for the potential role of *MED12* mutations in CRC, we studied CRC cell lines that differ substantially in the expression level of *MED12*, and found the latter to be correlated inversely with transforming growth factor (TGF)- β signalling and directly with apoptosis in response to chemotherapeutic agents. Importantly, these correlations were replicated when *MED12* expression was experimentally manipulated.

Conclusions Our data expand the recently described role of *MED12* as a tumour suppressor in other cancers to include CRC, and suggest TGF- β signalling as a potential mediator of this effect.

INTRODUCTION

Colorectal cancer (CRC) is a very common cancer that is only second to breast cancer in women, and lung and prostate cancer in men, and is the second leading cause of cancer death in Western countries.^{1–2} In the USA alone, it is estimated that 134 000 persons will be found to have CRC and that 49 000 will die from it. These alarming figures, however, are at least 40% lower than the mid-1980s thanks in large part to the implementation of preventive screening programmes that were conceived on the basis of improved understanding of CRC pathogenesis.^{3–4}

The seminal proposal by Vogelstein *et al* in 1988 laid the ground for the contemporary view of the

Significance of this study

What is already known on this subject?

- Colorectal cancer is known to develop as a multistep process involving driver mutations.
- *MED12* mutations are known to drive several tumour types.

What are the new findings?

- We show that *MED12* is recurrently mutated in colorectal cancer, uniformly in the active (unmethylated) X chromosome.
- We also show that *MED12* deficiency confers resistance to chemotherapy at the tissue culture level.

How might it impact on clinical practice in the foreseeable future?

- *MED12* mutations identified through genomic sequencing of colorectal cancer may predict resistance to chemotherapy.

transformation of intestinal epithelium into invasive adenocarcinoma through a slow multistage mutational process.^{5–6} Efforts to identify mutations in tumour-suppressor genes and oncogenes that play a key role in the initial stages of CRC tumorigenesis were limited in scope due to technical challenges, although early attempts to sequence large sets of genes using Sanger sequencing have provided valuable insights.^{7–9} Recent advances in sequencing technology have propelled the implementation of genomic analysis of CRC, which greatly expanded the repertoire of driver mutations, both at the base pair (bp) and chromosomal scale.¹⁰

MED12 encodes a member of Mediator, a multi-protein complex involved in the transcriptional regulation of many genes by mediating the interaction of RNA polymerase with various transcriptional factors.¹¹ Germline mutations in this X linked gene are known to cause intellectual disability in various syndromic forms.¹² This was corroborated by mouse data that show a strict requirement for *MED12* level in normal gastrulation and neurulation.¹³ More recently, somatic mutations in *MED12* have been found to play a significant role in the aetiology of uterine leiomyoma, a finding that was reproduced in several cohorts.¹⁴

To cite: Siraj AK, Masoodi T, Bu R, *et al.* Gut 2018;67:663–671.

Subsequently, driver *MED12* mutations were identified in other tumours including adrenocortical carcinoma, prostate cancer and breast fibroadenoma.^{15–17} Interestingly, the distribution of *MED12* mutations differs in different types of tumour. In uterine leiomyoma, most of *MED12* mutations were identified in exon 2 and lead to the activation of WNT pathway genes through interaction with β -catenin, while in prostate cancer *MED12* mutations were mainly detected in the non-N-terminal region and seem to influence *p53* and androgen signalling pathway.^{16 18–21}

In this study, we implemented a hypothesis-free genomics approach in our search for relevant somatic mutations in CRC in Saudi Arabia, a country with a particularly high incidence of CRC with an unusually young age of onset.²² This allowed us to identify recurrent somatic *MED12* mutations suggesting a potential role in CRC pathogenesis. Furthermore, functional analysis of relevant cell lines supports a previously reported role of *MED12* deficiency in mediating drug resistance.²³

MATERIALS AND METHODS

Human subjects

A total of 427 patient samples diagnosed with CRC at the King Faisal Specialist Hospital and Research Centre were collected from Department of Pathology. Detailed clinicopathological data were noted from case records and summarised in table 1. All tissue and blood samples were obtained from patients with approval from Institutional Review Board of the hospital. Informed consent was obtained from the patients from whom fresh cancer tissues were harvested for the study. For the study, waiver of consent was obtained for archived paraffin tissue blocks from Research Advisory Council (RAC) under project RAC#2140 005.

Table 1 Clinicopathological variables for the patient cohort (n=427)

<i>Age</i>	
Median	57.0
Range (IQR)	47.0–68.0
<i>Gender</i>	
Male	225 (52.7)
Female	202 (47.3)
<i>Status</i>	
Alive	328 (76.8)
Dead	96 (22.5)
Unknown	3 (0.7)
<i>Histological grade</i>	
Well differentiated	42 (9.8)
Moderately differentiated	324 (75.9)
Poorly differentiated	51 (11.9)
Unknown	10 (2.3)
<i>Tumour site</i>	
Left	345 (80.8)
Right	77 (18.0)
Unknown	5 (1.2)
<i>Tumour, node, metastases stage</i>	
I	50 (11.7)
II	149 (34.9)
III	161 (37.7)
IV	49 (11.5)
Unknown	18 (4.2)

DNA isolation

DNA isolation from peripheral blood, fresh frozen and paraffin-embedded tissues was performed using Gentra DNA isolation kit (Gentra, Minneapolis, Minnesota, USA) following the manufacturer's recommendations.

Whole genome sequencing

Whole genome sequencing was performed on 27 patients with their corresponding normal blood. Paired-end libraries of approximately 500-bp inserts were sequenced as 150-bp paired-end reads. Raw sequencing data were processed by an ultrafast Isaac DNA sequence aligner designed to align next-generation sequencing data with low-error rates using human genome V19. The Isaac Variant Caller was used to call single-nucleotide variants (SNVs) and small indels from the bam files.²⁴ SnpEff was used for annotating the variants with dbSNP138, dbSNP142, 1000 Genomes project and ESP6500 database.²⁵ We excluded common single-nucleotide polymorphisms (SNPs) with minor allele frequency of >0.001 as recorded in either dbSNP, National Heart, Lung, and Blood Institute exome sequencing project, 1000 Genomes and our in-house data from exome sequencing of over 730 normal samples. Non-coding variants, synonymous variants and variants present in highly repetitive regions were excluded for further analysis.

Candidate gene capture and sequencing

Recurrently mutated genes (mutated in at least three samples) from the 27 whole genome cases were selected for capture sequencing using SureSelect Target Enrichment Kit on Illumina HiSeq 2500 Sequencer. Fastq files were aligned to the human reference genome hg19 using burrows-wheeler aligner (BWA).²⁶ Local realignment, PCR duplicates and base quality recalibration was performed using genome analysis toolkit (GATK) and Picard-tools.²⁷ SNVs and small indels were called using GATK. The identified variants were annotated using SnpEff. Similar filters as applied to whole genome samples were used to get final mutation list.

PCR and Sanger sequencing

Primer 3 software was used to design the primers for the particular variants identified by whole exome or capture sequencing. PCR and Sanger sequencing were performed as described previously.²⁸ Reference sequences were downloaded from GenBank. Sequencing traces were analysed using the Mutation Surveyor V4.04 (Soft Genetics, State College, Pennsylvania, USA).

Allele-specific mutation analysis

Genomic DNA samples were digested using restriction endonuclease Mse I for 2 hours and then MethylCollector Ultra kit (Active Motif, Carlsbad, California, USA) was used to collect the pure/enriched methylated DNA and the counterpart unmethylated/methylated DNA following the manufacturer's recommendations as described previously.²⁹ PCR and Sanger sequencing were then performed to examine which allele of X chromosome has the identified mutation in female mutation-positive cases.

Tissue culture experiments

All human CRC cell lines; CL34, Caco2, Colo-320, DLD1, HCT15, HCT116, HT29 and LOVO were obtained from American Type Culture Collection and cultured in Roswell Park Memorial Institute 1640 media supplemented with 10% fetal

bovine serum (FBS), 100 U/mL penicillin, 100 U/mL streptomycin at 37°C in a humidified atmosphere containing 5% CO₂. All treatment experiments were performed in reduced FBS condition (5%). Apoptosis analysis was performed using annexin V/propidium iodide dual staining and measured by flow cytometry as previously described.³⁰ Antibodies against MED12 (CST#14360), E-cadherin (CST#3195), N-cadherin (CST#14215), pERK1/2 (CST#4370), ERK1/2 (CST#4695) and β-actin (CST#3700) were purchased from Cell Signaling Technology (Danvers, Massachusetts, USA). Antibodies against transforming growth factor (TGF)-β-R2 (sc#17799), vimentin (sc#5565) and GAPDH (sc#25778) were purchased from Santa Cruz Biotechnology (Santa Cruz, California, USA). Twist antibody (ab#175430) was purchased from Abcam (Cambridge, Massachusetts, USA).

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays

Initially, CRC cells were incubated at the concentration of 10⁴ cells per well in triplicates in a 96-well format. Cells were then treated with various doses of 5-fluorouracil (5-FU) for 48 hours in a final volume of 0.2 mL. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell viability assay, as previously described,³¹ 6 wells for each dosage including vehicle control were analysed for each experiment.

Gene silencing using small interfering RNA

Two different sets of MED12 small interfering RNA (siRNA), and scrambled control siRNA were purchased from OriGene (Rockville, Maryland, USA). Cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, California, USA) for 6 hours following which the lipid and siRNA complex was removed and fresh growth medium was added. After 48 hours of transfection cells were used for various experiments such as clonogenic assay, apoptosis analysis and immunoblotting.

Plasmid and transfection

Plasmid DNA encoding human MED12 was purchased from OriGene. Transfection was performed using Lipofectamine 2000 according to the manufacturer's protocol. Briefly, CRC cells were seeded in 6-well culture plates; when approximately 50% confluent, cells were transfected with 4 μg plasmid. After 48 hours of transfection cells were used for various experiments such as clonogenic assay, apoptosis analysis and immunoblotting.

Immunofluorescence analysis

CRC cells grown on coverslips in 6-well plates were fixed with ice-cold 100% methanol followed by permeabilisation with 0.2% Triton X-100, blocked with 5% horse serum in phosphate-buffered saline (PBS) solution, and incubated with antibodies to MED12 (1:200), TGF-β-R2 (1:50) or E-cadherin (1:200) in buffer A (1% bovine serum albumin, 0.1% Triton X-100, 10% horse serum in PBS solution) for 1 hour at 37°C. Cells were then incubated with Alexa Fluor 488 goat antirabbit or Alexa Fluor 594 goat antimouse antibody and mounted using DAPI. The cells were visualised using Olympus BX63 fluorescence microscope.

RESULTS

Whole genome sequencing identified MED12 among other recurrently mutated genes in CRC

Our bioinformatics analysis of whole genome sequencing (WGS) performed on the tumour and corresponding blood-

derived DNA from 27 patients with CRC identified 8356 non-synonymous somatic mutations. The average sequencing coverage for tumour samples was 36×, whereas for the corresponding normal, the coverage was 35×. All the samples were sequenced with an average read length of 150 bp. We categorised our cases into two groups based on microsatellite instability (MSI) status and mutations in mismatch excision repair (MMR) genes *MLH1*, *MLH3*, *MSH2*, *MSH3*, *MSH6* and *PMS2*. Six samples were MSI or MMR mutation positive. The average non-synonymous somatic mutation rate for these cases was 1052. Interestingly, one of these six cases harbouring *MSH3* and *POLE* mutations showed very high non-synonymous mutation density of 4157. The MSI-negative cases showed an average non-synonymous mutation density of 97 (table 2). The average synonymous somatic mutation rate for the six MSI-positive or MMR-positive cases was 373, while for the MSI low cases was 52. There were significantly more non-synonymous mutations compared with synonymous somatic mutations for the MSI-low cases ($p < 0.001$), whereas no significance was found in the MSI-high positive cases ($p = 0.305$, see online supplementary figure S1). We also found no significant difference between the number of non-synonymous and

Table 2 Comparison of non-synonymous mutation density with other exome studies

	Our data 27 samples		TCGA ¹⁰		Ana I. Robles et al ³²	Sanz-Pamplona et al ³³
	MSI-H	MSI-L	MSI-H	MSI-L	MSI-L	MSI-L
N	6	21	36	192	30	42
Mean	1052	97	1326	60	60	59
Median	385	96	689	54	58	62

Table 3 List of recurrent mutations found in 27 WGS and 400 capture sequencing cases

Gene	WGS		Capture sequencing		
	Mutant cases		Total mutant	Total	Frequency
<i>TP53</i>	6	245	251	425	59.06
<i>APC</i>	9	233	242	420	57.62
<i>KRAS</i>	4	171	175	425	41.18
<i>SYNE1</i>	4	58	62	424	14.62
<i>RYR1</i>	4	50	54	417	12.95
<i>MED12</i>	3	9	12	426	2.82

Table 4 Ranking of recurrently mutated genes with bases on mutation rate

Rank	Gene	No. of somatic mutations	AA length	Rate of somatic mutations
1	<i>KRAS</i>	4	189	1.768
2	<i>TP53</i>	7	393	1.488
3	<i>APC</i>	10	2843	0.294
4	<i>MED12</i>	3	2180	0.115
5	<i>RYR1</i>	4	5033	0.066
6	<i>SYNE1</i>	4	8797	0.038

Table 5 *MED12* mutations with three different pathogenicity scores

ID	Chr	POS	REF	ALT	Mutation	HGVS.c	HGVS.p	PolyPhen	SIFT	CADD
112-084	Chr X	70338672	A	G	Missense	c.68A>G	p.Asp23Gly	0.904	0	29
300-013	Chr X	70342408	G	T	Missense	c.1299G>T	p.Gln433His	0.994	0.006	19.6
300-074	Chr X	70344018	G	A	Missense	c.1754G>A	p.Arg585Gln	0.027	0.585	23
300-298	Chr X	70345918	C	T	Missense	c.2455C>T	p.Arg819Trp	0.994	0.001	32
300-300	Chr X	70349536	C	T	Missense	c.3698C>T	p.Ala1233Val	0.982	0.052	25.9
300-074	Chr X	70349689	G	T	Missense	c.3851G>T	p.Arg1284Leu	0.582	0.005	25.1
300-090	Chr X	70356162	C	T	Missense	c.5057C>T	p.Ser1686Leu	1	0.022	33
112-084	Chr X	70356420	C	A	Missense	c.5315C>A	p.Pro1772Gln	0.228	0.05	23.9
300-004	Chr X	70357181	G	A	Missense	c.5696G>A	p.Arg1899Gln	0.96	0.308	23.1
300-211	Chr X	70344030	A	T	Missense	c.1766A>T	p.Glu589Val	0.996	0.005	29.5
197-019	Chr X	70360698	G	GATC	Insertion	c.6268_6270dupATC	p.Ile2090dup	NA	NA	14.6
300-004	Chr X	70361090	AACAGCA	A	Deletion	c.6294_6299delACAGCA	p.Gln2098_Gln2099del	NA	NA	17.1
CRC-161	Chr X	70339253	G	A	Missense	c.130G>A	p.Gly44Ser	1	0	27.3
CRC-181	Chr X	70339233	C	T	Missense	c.110C>T	p.Thr37Met	1	0.001	20.5
CRC-302	Chr X	70361159	A	ACCAGCAGCAACA	Insertion	c.6369_6380dupCCAGCAGCAACA	p.His2123_Gln2126dup	NA	NA	0.8

Most of the mutations were predicted to be pathogenic by at least two prediction algorithms.

A SIFT score of ≤ 0.05 indicates the amino acid substitution is pathogenic (damaging), whereas a score of ≥ 0.05 is predicted to be tolerant. PolyPhen predicts results of nsSNPs as possibly damaging and probably damaging (PSIC > 0.5) or benign (PSIC < 0.5). According to CADD classification, variants with a C-score of 10 or greater ($\geq C10$) are probable functional variants, variants with a C-score of 20 or greater ($\geq C20$) are most deleterious and variants with a C-score of 30 or greater ($\geq C30$) are lethal. Pathogenic mutation scores are highlighted in bold.

ALT, altered; CADD, combined annotation dependent depletion; Chr, chromosome; CRC, colorectal cancer; NA, not applicable; PSIC, position-specific independent counts; POS, position; REF, reference; SIFT, sorting intolerant from tolerant.

synonymous mutations per sample and patient age in both the groups ($p=0.5922$).

In this discovery cohort, we prioritised genes that are somatically mutated in at least three patients as likely candidate 'driver' genes (see online supplementary table S1). Reassuringly, the list includes the well-established CRC driver genes *APC*, *KRAS* and *TP53* (table 3). In addition, the list also includes the following candidate genes: *RYR1*, *SYNE1* and *MED12*. Other well-known driver genes of CRC like *BRAF* and *SMAD4* were not found in our initial small cohort of 27 samples, however, we have found *PIK3CA* mutated in just 1 case. *MED12* was particularly interesting given its recently established role as a driver gene in a number of tumours and largely uncharacterised role in CRC.^{14–17} Furthermore, when recurrently mutated genes in our discovery cohort were ranked based on the relative mutation frequency by taking the protein size into account,^{34–35} *MED12* ranked fourth to *APC*, *KRAS* and *TP53* (table 4). The following likely pathogenic somatic variants were identified in *MED12*: c.110C>T;p.Thr37Met, c.130G>A;p.Gly44Ser and c.6369_6380dupCCAGCAGCAACA; p.His2123_Gln2126dup (table 5).

To further investigate a potential role of *MED12* in CRC, we sequenced *MED12* in a replication cohort of 400 patients with CRC using in-solution capture and next-generation sequencing. One sample was not sequenced due to quality control (QC) failure. Using a stringent filtering pipeline, we identified 15 likely pathogenic variants in *MED12*, 11 of which were confirmed by Sanger sequencing to be true somatic mutations in 9 cases (table 5; figure 1 and see online supplementary figure S2). Most of these mutations were pathogenic as predicted by three different computational algorithms.

Therefore, by combining the discovery and replication cohort, the percentage of patients with somatic *MED12* mutations is 2.8%, a small but comparable percentage to some of the known driver genes in CRC, for example, *BRAF*, *PTEN*, *NRAS*, *SMAD4* and *MUTYH*.^{10–36–38} We found a total of 14 *MED12* gene mutations in 12 CRC cases in this cohort. Out of 14 mutations, 11 were missense, 2 duplication and 1 deletion. Three mutations were seen in exon 1, two mutations were seen in exon 13, 37, 43 each and one mutation was found in exon 9, 18, 27, 39 and 42 each. The concurrent presence of nearly all of these *MED12* somatic mutations with mutations in well-

Figure 1 Schematic diagram of distribution of 14 *MED12* mutations identified in 12 colorectal cancer cases.

Figure 2 Sanger sequencing electropherogram of inactive/active allele of *MED12* gene on chromosome X in eight female cases harbouring *MED12* mutations. Top panel: sequencing electropherogram of enriched methylated DNA indicating no mutation was identified on the inactive allele caused by methylation. Lower panel: sequencing electropherogram of enriched unmethylated and unbound methylated DNA. WT, wild type.

established driver genes suggests a potential role in tumour evolution past the initiation stage.²⁸ Unexpected for an X linked gene, only 33% (4/12) patients with CRC with somatic *MED12* mutations were males. This prompted us to investigate whether *MED12*-mutated females harboured their somatic mutations on the active allele X chromosome, essentially mimicking the effect of hemizygous male mutations. Indeed, in all eight females the presence of somatic *MED12* mutation on the active allele of the chromosome X rather than inactive imprinted allele was confirmed (figure 2). Unfortunately, the relatively small number of *MED12*-mutated patients precluded formal testing for such associations as disease severity, response to chemotherapy and survival. However, it is worth noting that 50% of *MED12*-mutated patients with CRC who underwent

chemotherapy (4/8) showed poor response to standard chemotherapy.

***MED12* is a likely tumour suppressor that modulates TGF- β -induced epithelial-mesenchymal transition signalling in CRC cell lines**

In order to gain insight into the biological plausibility of *MED12* mutations in the pathogenesis of CRC, which would be suggested by our finding above, we set out to test its potential role in relevant CRC cell lines. To determine the role of *MED12* expression in vitro, we assessed expression of *MED12* in a panel of eight CRC cell lines by immunoblotting. As shown in figure 3A, there was differential expression of *MED12* in these cell lines. On the basis of *MED12* expression, we

Figure 3 (A) Expression of *MED12* in colorectal cancer (CRC) cell lines. Proteins were isolated from eight CRC cell lines and immunoblotted with antibodies against *MED12* and GAPDH. (B) Representative images of fluorescence immunostaining for *MED12* in four selected CRC cell lines and confirm results from western blot analysis. (C and D) CRC cells were treated with increasing doses of 5-fluorouracil (FU) for 48 hours and cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (C) and apoptosis by flow cytometry after staining the cells with annexin V/propidium iodide (D). Data presented in the bar graphs are the mean $\pm$ SD of three independent experiments. *Indicates a statistically significant difference compared with control with $p < 0.05$.

identified two CRC cell lines; DLD1 and LOVO that had overexpression of *MED12* as well as two; Colo-320 and HT29 that had negligible expression, for further experimentation. *MED12* abundance in these cells was also verified by immunofluorescence analysis (figure 3B). Using these cell lines, we determined the response to 5-FU treatment in inhibiting cell viability and inducing apoptosis. There was inhibition of cell viability and induction of apoptosis in both cell lines that had overexpression of *MED12*; however, 5-FU treatment had no effect on cell viability and induced minimal apoptotic response in the other two cell lines (figure 3C, D). Next, to confirm the role of *MED12* in chemosensitivity, we downregulated the expression of *MED12* using *MED12*-specific siRNA. As shown in figure 4A, B, silencing of *MED12* significantly increased the proliferation of LOVO and DLD1 cells as confirmed by clonogenic assay. Following downregulation of *MED12*, we treated these cells with 5-FU for 48 hours and analysed the cells for apoptosis. As shown in figure 4C, when knocked down for *MED12*, DLD1 and LOVO cells became resistant to 5-FU treatment as compared with CRC cells transfected with non-specific scrambled siRNA. This was further confirmed using another set of *MED12* siRNA that showed similar results (see online supplementary figure S3). *MED12* has been shown to mediate response to alkylating agents and epidermal growth factor receptor inhibitors through the RAS pathway. Specifically, *MED12* was found to suppress TGF- β signalling and that the latter is what mediates drug resistance.²³ Therefore, we asked whether the effect we observed in CRC cell lines is similarly mediated by TGF- β . Indeed, we show that *MED12* level is inversely correlated with TGF- β signalling as visualised by western blot analysis where *MED12* knockdown led to upregulation of TGF- β -R2 and activation of ERK in both *MED12* expressing cell lines (Figure 4D

and see online supplementary figure S3). TGF- β is known to induce an epithelial-mesenchymal transition, leading to the loss of epithelial adhesion molecule E-cadherin and induction of several mesenchymal markers such as vimentin and N-cadherin.²³ Silencing of *MED12* decreased the E-cadherin expression with an accompanying upregulation of N-cadherin, vimentin and Twist expressions in *MED12* expressing cells (figure 4D and see online supplementary figure S3). Similar results were observed by immunofluorescence where knock-down of *MED12* induces TGF- β -R2 and decreases E-cadherin expressions in *MED12* expressing cells (figure 4E). Conversely, forced expression of *MED12* decreases cell proliferation in *MED12* low expressing cells as shown by clonogenic assay (figure 5A, B). Forced expression of *MED12* in Colo-320 and HT29 cells also sensitised them to 5-FU treatment as compared with cells transfected with empty vector (figure 5C). Moreover, *MED12* overexpression in Colo-320 and HT29 cells markedly decreased TGF- β -R2 expression with an accompanying increased E-cadherin and decreased N-cadherin, vimentin and Twist expression compared with empty vector transfected cells (figure 5D). These results were further confirmed by immunofluorescence analysis (figure 5E). Taken together, these data suggest a potential role for *MED12* in sensitising CRC cells to chemotherapy.

DISCUSSION

Several studies have attempted to characterise the mutational landscape of CRC and several novel candidate driver genes have emerged as a result. We found a total of 14 *MED12* gene mutations in 12 CRC cases in this cohort. Out of 14 mutations, 11 were missense, 2 duplication and 1 deletion. Three mutations were seen in exon 1, 2 mutations were seen in exon 13, 37, 43

Figure 4 Silencing of *MED12* increases the chemoresistance in colorectal cancer (CRC) cell lines. (A and B) CRC cells were transfected with either scrambled siRNA or *MED12*-specific small interfering RNA (siRNA) for 48 hours and clonogenic assay were performed. Cells (6×10^2) after post-transfection were seeded into each of three dishes (60 mm diameter), and grown for an additional 10 days, then stained with crystal violet (A). Colony numbers in the entire dish were counted (B). (C) CRC cells were transfected with either scrambled siRNA or *MED12* siRNA and subsequently treated with 50 and 100 μ M 5-fluorouracil (FU) for 48 hours. Following treatment, cells were analysed for apoptosis by flow cytometry. (D) LOVO and DLD1 cells were transfected with either scrambled siRNA or *MED12*-specific siRNA for 48 hours. Proteins were isolated and immunoblotted with antibodies against *MED12*, transforming growth factor (TGF)- β -R2, p-ERK1/2, ERK1/2, E-cadherin, N-cadherin, vimentin, Twist and β -actin for equal loading. (E) Representative images of fluorescence immunostaining for *MED12*, TGF- β -R2 and E-cadherin in LOVO and DLD1 cells after post-transfection with *MED12* siRNA. Data presented in the bar graphs are the mean $\pm$ SD of three independent experiments. *Indicates a statistically significant difference compared with control with $p < 0.05$.

each and 1 mutation was found in exon 9, 18, 27, 39 and 42 each. The Cancer Genome Atlas Network in their analysis on 224 CRCs found 15 *MED12* mutations in 14 CRC cases.¹⁰ In their study they found, out of 15 mutations, 10 were missense, 4 were silent and 1 mutation was in-frame deletion. Mutation were seen in exon 36 (2 mutations), exon 42 (2 mutations) and 1 mutation each in exon 1, 2, 5, 7, 10, 18, 23, 29, 35, 40 and 43. Mutation in exon 2 of *MED12* gene is the most common genetic aberration present in roughly 64% of leiomyomas.³⁹ Although very rare, *MED12* mutations in leiomyoma have also been reported in other regions of gene such as intron 1⁴⁰ and exon 1.⁴¹ In leiomyoma, codon 44 is the most common hotspot for *MED12* mutation and both missense and in-frame insertion-deletion mutations are seen.⁴²

The large study by the Cancer Genome Atlas Network did not highlight *MED12* as a likely candidate even though 15 somatic mutations were identified, most likely because of the small percentage of affected samples.¹⁰ Indeed, Kämpjärvi *et al*⁴³ specifically sequenced exon 2 *MED12* in 392 patients with cancer and identified only two patients with somatic mutations. This is consistent with our data where we show that only 2.8% of patients with CRC have somatic *MED12* mutations.

Genes in the RAS pathway are known to contribute to the pathogenesis of CRC, most notably *KRAS* and *BRAF* in which somatic mutations are observed in 30%–40% and 10%, respectively, of patients with CRC.^{44–45} These somatic mutations are typically activating in nature and are associated with the activation of the Erk1/2 kinase pathway.⁴⁶ Thus, our finding that *MED12* deficiency is also associated with the activation of the Erk1/2 kinase pathway would be consistent with the proposed oncogenic potential of *MED12* somatic mutations in CRC. Although the numbers are small, we observed a trend where *MED12*-mutated patients with CRC have high likelihood of displaying resistance to alkalinising chemotherapeutic agents. This appears to be consistent with our finding in CRC cell lines where we show that *MED12* mediates sensitivity to 5-FU, likely via suppressing TGF- β signalling, a finding that was also obtained by Huang *et al*²³ using different cell lines.

The location of *MED12* on the X chromosome provides a unique advantage, where biallelic inactivation can be acquired as a one-step rather than the traditional two-step loss of heterozygosity (LOH) process.⁴⁷ In other words, because females are functionally hemizygous for *MED12*, somatic mutations in the active X chromosome can result in complete inactivation of the gene. This has been shown in *MED12*-related breast

Figure 5 Forced expression of *MED12* decreases the chemoresistance in colorectal cancer (CRC) cell lines. (A and B) CRC cells were transfected with either empty vector or *MED12* pcDNA for 48 hours and clonogenic assay were performed. Cells (6×10^2) after post-transfection were seeded into each of three dishes (60 mm diameter), and grown for an additional 10 days, then stained with crystal violet (A). Colony numbers in the entire dish were counted (B). (C) CRC cells were transfected with either empty vector or *MED12* pcDNA and subsequently treated with 50 and 100 μ M 5-fluorouracil (FU) for 48 hours. Following treatment, cells were analysed for apoptosis by flow cytometry. (D) COLO-320 and HT29 cells were transfected with either empty vector or *MED12* pcDNA for 48 hours. Proteins were isolated and immunoblotted with antibodies against *MED12*, transforming growth factor (TGF)- β -R2, p-ERK1/2, ERK1/2, E-cadherin, N-cadherin, vimentin, Twist and GAPDH for equal loading. (E) Representative images of fluorescence immunostaining for *MED12*, TGF- β -R2 and E-cadherin in COLO-320 and HT29 cells after post-transfection with *MED12* pcDNA. Data presented in the bar graphs are the mean $\pm$ SD of three independent experiments. *Indicates a statistically significant difference compared with control with $p < 0.05$.

fibroadenoma and leiomyoma.^{17 48} Our finding that all female patients with CRC with somatic *MED12* mutations harboured the mutations on their active X chromosome serves as an additional line of evidence in support of these mutations playing a role in driving CRC tumorigenesis. The 'single-hit' requirement for inactivating *MED12* in females, likely explains the lack of male predominance as expected for an X linked gene and represents a hypothetical opportunity for treatment through reactivating (demethylating) the normal X chromosome in these patients to restore normal level of *MED12*. We will pursue this as a future research direction.

In conclusion, we show that *MED12* is recurrently mutated in Saudi patients with CRC and propose this corroborates previously proposed tumour suppressor role. Our data also suggest that such a role may be mediated through antagonising TGF- β signalling.

Acknowledgements We thank Wael Haqawi, Zeeshan Qadri, Dionne Rae Rala, Ingrid Francesca Victoria, Maha Al Rasheed, Khadija Al Obaisi, Roxanne

Melosantos, Rafia Begum, Sarah Siraj and Saravanan Thangavel for technical assistance.

Contributors We have added as a coauthor a team member who helped generate the additional data in functional analyses (PP).

Competing interests None declared.

Patient consent Obtained.

Ethics approval Research ethics committee, King Faisal Specialist Hospital and Research Centre.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. *Ann Oncol* 2005;16:481–8.

- 2 Quinn M, Babb P, Brock A, *et al.* Cancer trends in England and Wales, 1950–1999. *Health Stat Q* 2000;5–19.
- 3 Welch HG, Robertson DJ. Colorectal cancer on the decline—why screening can't explain it All. *N Engl J Med* 2016;374:1605–7.
- 4 Holme Ø, Bretthauer M, Frøtheim A, *et al.* Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. *Cochrane Database Syst Rev* 2013;(9):CD009259.
- 5 Vogelstein B, Fearon ER, Hamilton SR, *et al.* Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988;319:525–32.
- 6 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990;61:759–67.
- 7 Wood LD, Parsons DW, Jones S, *et al.* The genomic landscapes of human breast and colorectal cancers. *Science* 2007;318:1108–13.
- 8 Greenman C, Stephens P, Smith R, *et al.* Patterns of somatic mutation in human cancer genomes. *Nature* 2007;446:153–8.
- 9 Sjöblom T, Jones S, Wood LD, *et al.* The consensus coding sequences of human breast and colorectal cancers. *Science* 2006;314:268–74.
- 10 Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 2012;487:330–7.
- 11 Taatjes DJ. The human Mediator complex: a versatile, genome-wide regulator of transcription. *Trends Biochem Sci* 2010;35:315–22.
- 12 Graham JM, Schwartz CE. MED12 related disorders. *Am J Med Genet A* 2013;161A:2734–40.
- 13 Rocha PP, Scholze M, Bleiss W, *et al.* Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling. *Development* 2010;137:2723–31.
- 14 Kämpjärvi K, Mäkinen N, Mehine M, *et al.* MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas. *Br J Cancer* 2016;114:1405–11.
- 15 Assié G, Letouzé E, Fassnacht M, *et al.* Integrated genomic characterization of adrenocortical carcinoma. *Nat Genet* 2014;46:607–12.
- 16 Barbieri CE, Baca SC, Lawrence MS, *et al.* Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. *Nat Genet* 2012;44:685–9.
- 17 Lim WK, Ong CK, Tan J, *et al.* Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. *Nat Genet* 2014;46:877–80.
- 18 Halder SK, Laknaur A, Miller J, *et al.* Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids. *Mol Genet Genomics* 2015;290:505–11.
- 19 Kim S, Xu X, Hecht A, *et al.* Mediator is a transducer of Wnt/beta-catenin signaling. *J Biol Chem* 2006;281:14066–75.
- 20 Wang Q, Sharma D, Ren Y, *et al.* A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression. *J Biol Chem* 2002;277:42852–8.
- 21 Donner AJ, Szostek S, Hoover JM, *et al.* CDK8 is a stimulus-specific positive coregulator of p53 target genes. *Mol Cell* 2007;27:121–33.
- 22 Beg S, Siraj AK, Prabhakaran S, *et al.* Molecular markers and pathway analysis of colorectal carcinoma in the Middle East. *Cancer* 2015;121:3799–808.
- 23 Huang S, Hölzel M, Knijnenburg T, *et al.* MED12 controls the response to multiple cancer drugs through regulation of TGF- β receptor signaling. *Cell* 2012;151:937–50.
- 24 Racz C, Petrovski R, Saunders CT, *et al.* Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms. *Bioinformatics* 2013;29:2041–3.
- 25 Cingolani P, Platts A, Wang Le L, *et al.* A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly (Austin)* 2012;6:80–92.
- 26 Li H, Durbin R. Fast and accurate long-read alignment with Burrows–Wheeler transform. *Bioinformatics* 2010;26:589–95.
- 27 McKenna A, Hanna M, Banks E, *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010;20:1297–303.
- 28 Siraj AK, Masoodi T, Bu R, *et al.* Genomic profiling of thyroid cancer reveals a role for thyroglobulin in metastasis. *Am J Hum Genet* 2016;98:1170–80.
- 29 De Meyer T, Mampaey E, Vlemmix M, *et al.* Quality evaluation of methyl binding domain based kits for enrichment DNA-methylation sequencing. *PLoS ONE* 2013;8:e59068.
- 30 Ahmed M, Hussain AR, Bavi P, *et al.* High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma. *Carcinogenesis* 2014;35:1564–72.
- 31 Hussain AR, Ahmed SO, Ahmed M, *et al.* Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. *PLoS ONE* 2012;7:e39945.
- 32 Robles AI, Traverso G, Zhang M, *et al.* Whole-exome sequencing analyses of inflammatory bowel disease-associated colorectal cancers. *Gastroenterology* 2016;150:931–43.
- 33 Sanz-Pamplona R, Lopez-Doriga A, Paré-Brunet L, *et al.* Exome sequencing reveals AMER1 as a frequently mutated gene in colorectal cancer. *Clin Cancer Res* 2015;21:4709–18.
- 34 Schell MJ, Yang M, Teer JK, *et al.* A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. *Nat Commun* 2016;7:11743.
- 35 Lawrence MS, Stojanov P, Polak P, *et al.* Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nat* 2013;499:214–18.
- 36 Malapelle U, Pisapia P, Sgariglia R, *et al.* Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. *J Clin Pathol* 2016;69:767–71.
- 37 Chang YC, Chang JG, Liu TC, *et al.* Mutation analysis of 13 driver genes of colorectal cancer-related pathways in Taiwanese patients. *World J Gastroenterol* 2016;22:2314.
- 38 Yu J, Wu WK, Li X, *et al.* Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. *Gut* 2015;64:636–45.
- 39 Croce S, Chibon F. MED12 and uterine smooth muscle oncogenesis: state of the art and perspectives. *Eur J Cancer* 2015;51:1603–10.
- 40 Wang H, Ye J, Qian H, *et al.* High-resolution melting analysis of MED12 mutations in uterine leiomyomas in Chinese patients. *Genet Test Mol Biomarkers* 2015;19:162–6.
- 41 Kämpjärvi K, Park MJ, Mehine M, *et al.* Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas. *Hum Mutat* 2014;35:1136–41.
- 42 Heinonen HR, Sarvlinna NS, Sjöberg J, *et al.* MED12 mutation frequency in unselected sporadic uterine leiomyomas. *Fertil Steril* 2014;102:1137–42.
- 43 Kämpjärvi K, Mäkinen N, Kilpivaara O, *et al.* Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. *Br J Cancer* 2012;107:1761–5.
- 44 Phipps AI, Buchanan DD, Makar KW, *et al.* KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. *Br J Cancer* 2013;108:1757–64.
- 45 Barras D. BRAF mutation in colorectal cancer: an update. *Biomark Cancer* 2015;7:9.
- 46 Wiener Z, Band AM, Kallio P, *et al.* Oncogenic mutations in intestinal adenomas regulate Bim-mediated apoptosis induced by TGF- β . *Proc Natl Acad Sci U S A* 2014;111:E2229–36.
- 47 Liu Y, Wang L, Zheng P. X-linked tumor suppressors: perplexing inheritance, a unique therapeutic opportunity. *Trends Genet* 2010;26:260–5.
- 48 Mäkinen N, Mehine M, Tolvanen J, *et al.* MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. *Science* 2011;334:252–5.